Meeting The Challenge Of Pain Management In An Ever-Evolving Opioid Epidemic: 2024 - Final Assessment
Credits:
4.5 AMA PRA Category 1 Credit(s) ™
4.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 15, 2022
December 15, 2022
Primary Audience:
All providers eligible to prescribe opioid analgesics, including allopathic and osteopathic physicians, dentists and oral surgeons, physician assistants, nurse practitioners, pharmacists, and nurses and nurses involved in the care of patients receiving treatment for pain.
How much do you already know about safe opioid prescribing? This short self-assessment activity will let you test your knowledge about this ongoing public health challenge. Please follow the prompts to complete the self-assessment.
1.
Describe the scope and burden of chronic pain and opioid use disorder (OUD) in the United States
2.
Assess patients in pain and set goals for pain management and functionality
3.
Evaluate the range of therapeutic options for managing pain, including nonpharmacological and pharmacological therapies (non-opioid and opioid analgesics)
4.
Integrate opioid analgesics into an acute pain treatment plan individualized to the needs of the patient
5.
Counsel patients and caregivers about the use of naloxone for opioid overdose
6.
Safely and effectively manage patients on opioid analgesics for the treatment of chronic pain
7.
Analyze potential benefits with the risks of serious adverse outcomes when initiating, titrating, and discontinuing use of opioids
8.
Utilize safe opioid practices pursuant to evolving federal and state regulations and expert guidelines on treating pain and prescribing opioids
9.
Identify patients who may warrant referral to specialist care
10.
Counsel patients and caregivers about the safe use of opioid analgesics, including proper storage and disposal
11.
Outline evidence-based strategies for treatment of opioid use disorder (OUD)
12.
Explain the epidemiology and antecedents associated with disparities in opioid use disorder (OUD) in the United States, including differences in overdose rates and access to treatment between different racial and ethnic groups
